Global Small Cell Lung Cancer Therapeutics Market 2015-2019

Published: Mar 2015 Pages: 102 SKU: IRTNTR5579

Small cell lung cancer therapeutics industry insights

TechNavio's report, global small cell lung cancer therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the global small cell lung cancer therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Small cell lung cancer therapeutics market segments

Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer.

Small cell lung cancer is caused by smoking tobacco, or second-hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.

 
 
 

SCLC therapeutics market worth based on regions
• Americas
• APAC
• EMEA  
     
SCLC therapeutics market outlook for key vendors
• Bristol-Myers Squibb
• GlaxoSmithKline
• Menarini
• Sanofi
• ZIOPHARM Oncology

SCLC therapeutics market driver
• High Unmet Need
• For a full, detailed list, view our report

SCLC therapeutics market challenge
• High Cost of Treatment
• For a full, detailed list, view our report

SCLC therapeutics market Trend
• Strategic Alliances
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

 

 

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Understanding the Disease
05.2 Classification
05.2.1 Small Cell Carcinoma
05.2.2 Combined Small Cell Carcinoma
05.3 Diagnosis
05.3.1 Physical Examination
05.3.2 Laboratory Tests
05.3.3 Chest X-ray
05.3.4 Sputum Cytology
05.3.5 CT Scan
05.3.6 Biopsy
05.3.7 Light and Electron Microscopy
05.3.8 Immunohistochemistry
05.4 Rate of Incidence and Prevalence
05.5 Staging
05.6 Management
05.7 Economic Burden
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Top Predictions
07.4 Five Forces Analysis
08 Pipeline Analysis
08.1 Key Information on the Pipeline Candidates
08.1.1 Palifosfamide (ZIO-201)
08.1.2 Ipilimumab+Etoposide+Cisplatin/Carboplatin
08.1.3 Ipilimumab
08.1.4 Enoxaparin Sodium
08.1.5 BAY1000394 (Roniciclib)
08.1.6 Nivolumab (ONO-4538/ BMS-936558)
08.1.7 BMS-986012
08.1.8 LY2940680
08.1.9 Sabarubicin (MEN 10755)
08.1.10 CAP7.1
08.1.11 SC16LD6.5
08.1.12 BIW-8962
08.1.13 AMG 479 (Ganitumab)
08.1.14 LY2510924
08.1.15 Trisenox
08.1.16 MGN1703
08.1.17 Tarextumab  (OMP-59R5)
08.1.18 BMN 673 (Talazoparib Tosylate)
08.1.19 NGR-hTNF
08.1.20 CPI-613
08.1.21 Alisertib (MLN8237)
08.1.22 Vismodegib (GDC-0449, Erivedge)
08.1.23 Cabozantinib (XL184 or Cometriq)
08.1.24 Selinexor  (KPT-330)
08.1.25 ADI-PEG 20 (Pegargiminase)
08.1.26 Etirinotecan Pegol (NKTR-102)
08.1.27 CRLX101 (IT-101 or Cyclodextrin-based Polymer-camptothecin IT-101)
08.1.28 NTX-010
08.1.29 Aldoxorubicin
08.1.30 HA-Irinotecan
08.1.31 Carfilzomib
08.1.32 Small Cell Lung Cancer Vaccine
08.1.33 GSK2879552
08.1.34 NV-344 (ME-344)
08.1.35 BMS-833923 (XL139)
08.1.36 PM01183 (Lurbinectedin)
08.1.37 LDE225 (Erismodegib or Sonidegib)
08.1.38 Belinostat
08.2 Timeline for Major Products under Development
08.2.1 Palifosfamide (ZIO-201)
08.2.2 Sabarubicin (MEN 10755)
09. Market Segmentation by Therapeutic Class of Drugs
09.1 Alkylating Agents
09.2 Antimetabolites
09.3 Microtubule Inhibitors
09.4 Cytotoxic Antibiotics
09.5 Topoisomerase Inhibitors
09.6 Others
10 Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11 Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
12 Geographical Segmentation
12.1 Small Cell Lung Cancer Market in Americas
12.1.1 Market Size and Forecast
12.2 Small Cell Lung Cancer Market in EMEA Region
12.2.1 Market Size and Forecast
12.3 Small Cell Lung Cancer Market in APAC Region
12.3.1 Market Size and Forecast
13 Buying Criteria
14 Market Growth Drivers
15 Drivers and their Impact
16 Market Challenges
17 Impact of Drivers and Challenges
18 Market Trends
19 Trends and their Impact
20 Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Bristol-Myers Squibb
20.2.2 GlaxoSmithKline
20.2.3 Menarini
20.2.4 Sanofi
20.2.5 ZIOPHARM Oncology
20.3 Other Prominent Vendors
21 Key Vendor Analysis
21.1 Bristol-Myers Squibb
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Key Product Offerings
21.1.4 Revenue by Geography
21.1.5 Business Strategy
21.1.6 Key Information
21.1.7 SWOT Analysis
21.2 GlaxoSmithKline
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Pipeline Products
21.2.7 Business Strategy
21.2.8 Key Information
21.2.9 SWOT Analysis
21.3 Menarini
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Pipeline Products
21.3.4 Recent Developments
21.3.5 SWOT Analysis
21.4 Sanofi
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 ZIOPHARM Oncology
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Recent Developments
21.5.4 SWOT Analysis
22 Other Reports in this Series

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

PURCHASE FULL REPORT OF

market

QUICK BUY

Key Questions Answered

  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis